SLS Joins MRNA And ANL In Biotech’s Top 3 This Year — Here’s How A Late-2025 Bet Could Grow 10x From Here
Sellas Life Sciences (SLS) reported positive Phase 3 trial results for its cancer vaccine, Galinpepimut-S (GPS), showing a 24-month median survival vs. 14.7 months in the control group. The company plans to meet with the FDA and aims to file for approval in early 2027. SLS also announced a $150M share offering to fund further development. Analysts and investors reacted positively, with some noting potential for expedited approval and broader applications.
How this was made
The 30-second read
Why it matters
The data represent a material clinical milestone that could accelerate FDA review and drive near‑term stock appreciation, while also prompting a $150 M capital raise.
Market read
The trial outcome is a primary disclosure for a U.S. biotech, likely influencing both the stock and the broader oncology immunotherapy space.
What to watch
Upcoming $150 M equity raise could dilute shareholders; timing of FDA filing and potential off‑label use add execution risk.
Background
Sellas Life Sciences (SLS) announced Phase 3 results for its GPS vaccine targeting WT1 in leukemia, showing significant survival benefit and a hazard ratio of 0.59.
Ticker impact
Sellas Life Sciences reported positive Phase 3 trial results for its GPS vaccine, showing a 9.3‑month survival benefit and a 41% reduction in risk of death.
potential upside as market prices in efficacy data and upcoming FDA filing
Phase 3 readout is a primary disclosure for a biotech; the magnitude of survival benefit is material and the company plans an FDA filing in H1‑2027.
Market effects
positive momentum for the oncology biotech sector as the trial validates WT1‑targeted vaccines
U.S. biotech market
moderate, may influence global investors tracking immunotherapy pipelines
Counterpoint
If the FDA requires additional data or the trial is not replicated, the stock could face sharp downside, especially after a large dilution raise.
Key entities
- companySellas Life Sciences
Biotech firm developing the GPS vaccine.
- individualMartin Shkreli
Commentator questioning the robustness of the trial results.

